DAINIPPON SUMITOMO PHARMA ENTERS INTO PARTNERSHIP AGREEMENT ON ANTI-HYPERTENSION AND HEPATOCELLULAR CANCER DRUGS

Dainippon Sumitomo Pharma (DSP) and Bristol-Myers K.K. (BMKK) have concluded an agreement on the marketing rights of anti-hypertension and hepatocellular cancer drug. Under the agreement terms, BMKK will sublicense to DSP the development, manufacturing/marketing and marketing rights of irbesartan, an anti-hypertension drug.
JCN Network